HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...
The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell disease, two rare blood disorders. Casgevy has been on the market for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback